Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Next events

BGV to Attend the 7ᵗʰ Annual Immuno-Oncology Innovation Forum

The 7th Annual IOIF takes place from 18-20 May. It will feature more than 14 hours of high-level speeches and panel discussions by leading industry stakeholders. This year, there is a global company showcase of about 25 presentations by established public, private,...

BioEquity 17-19 May 2021

The BGV team shall attend the Bio-Equity 2021 online conference. Partnering can be scheduled through the online platform. https://conferences.biocentury.com/bioequity-europe-2021  

Latest investments

Subscribe to BGV news updates

Join our mailing list to receive the latest news and updates from our team.

Privacy Policy

Please check your email to complete your subscription.